Faruqi and Faruqui, LLP Logo
Share this page

Progenics Pharmaceuticals, Inc. (PGNX)

(NasdaqGS: PGNX)

Summary

Faruqi & Faruqi, LLP Launches An Investigation Against Progenics Pharmaceuticals, Inc. (PGNX) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NasdaqGS: PGNX) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an increase in the number of available shares under the Company’s 2005 Stock Incentive Plan.

Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on May 3, 2013, the Board of Directors recommends that Progenics’ shareholders vote to approve an increase in the number of available shares under the Company’s 2005 Stock Incentive Plan from 8,450,000 to 10,450,000. The issuance of the additional shares could have a substantial dilutive effect on the shares of Progenics common stock.

If you own common stock in Progenics and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    Progenics Pharmaceuticals, Inc. (PGNX)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Juan E. Monteverde
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 05/10/2013

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.